Ozempic & Protein Powder: How Weight Loss Drugs Fuel Demand | Minneapolis Manufacturer

Puris Proteins, a Minneapolis-based manufacturer of pea and soy protein powders, has seen its revenue reach an estimated $200 million annually, fueled by growing demand from users of GLP-1 medications like Ozempic and Wegovy, according to a report published February 27, 2026, by Forbes.

The company, founded in 1985 by the Lorenzen family, has evolved from a little operation breeding soybeans in a basement to the largest pea protein manufacturer in the United States. CEO Tyler Lorenzen attributes the recent growth to the increasing focus on protein intake among individuals using GLP-1 drugs, which are prescribed for diabetes and weight loss.

“What GLP1-users all want is to get more protein in their diet,” Lorenzen told Forbes. “It needs to taste great and be more nutritious. That’s really why Puris is growing faster than our peers. People love what they eat, and then great taste is the on-ramp to healthy habits—and the flywheel for longevity begins.”

The surge in demand for pea protein reflects a broader trend toward plant-based diets and a desire for healthier food options, particularly among consumers seeking to maximize the benefits of medications like Ozempic. Newsclip.com reported that the company’s success is built on targeted marketing, quality control, and strategic pricing, positioning it as a lifestyle brand aligned with health-conscious consumers.

This “Ozempic generation,” as described in reports, is actively seeking food products that offer both health benefits and ethical sourcing. Daily Harvest highlights the importance of high-protein meals for individuals using semaglutide, the active ingredient in Ozempic and Wegovy, to maintain muscle mass and energy levels.

Puris Proteins’ growth comes as the food industry adapts to changing consumer preferences and the increasing prevalence of GLP-1 medications. The company’s ability to provide palatable and nutritious protein sources is seen as a key factor in its success, and a potential indicator of future trends in the food and health sectors.